• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by ANI Pharmaceuticals Inc. (Amendment)

    12/12/22 4:00:42 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANIP alert in real time by email
    SC 13D/A 1 tm2232474d1_sc13da.htm SC 13D/A

     

     

     

    UNITED STATES

     

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, DC 20549

     

    SCHEDULE 13D/A

     

    (Amendment No. 5)

     

    Under the Securities Exchange Act of 1934

     

    ANI Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    00182C103

    (CUSIP Number)

     

    Robert A. Graham

    MVP Capital Partners

    259 N. Radnor-Chester Road

    Suite 130, Radnor, PA  19087

    Tel:  (610) 254-2999

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    December 1, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 00182C103 13D
       

     

    1.

    Name of Reporting Persons

     

    Meridian Venture Partners II GP, L.P. (“GP”)

     

     
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ¨
         
      (b) x (1)
         
     
    3.

    SEC Use Only

     

     

     
    4.

    Source of Funds (See Instructions)

     

    OO

     

     
    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    ¨
       
     
    6.

    Citizenship or Place of Organization

     

    Delaware, United States of America

     

     

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

     

    0 shares

     

     
    8.

    Shared Voting Power

     

    2,019,259 shares of Common Stock

     

     
    9.

    Sole Dispositive Power

     

    0 shares

     

     
    10.

    Shared Dispositive Power

     

    2,019,259 shares of Common Stock

     

     

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,019,259 shares of Common Stock

     

     
    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
       
     
    13.

    Percent of Class Represented by Amount in Row 11

     

    11.6% (2)

     

     
    14.

    Type of Reporting Person (See Instructions)

     

    PN

     

     

     

     

    (1) This statement on Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2) Percentage is based on 17,453,805 shares of the Company’s Common Stock, par value $0.0001 per share, outstanding as of November 2, 2022, as reported on the Company’s Form 10-Q for the period ended September 30, 2022.

     

     

     

     

    CUSIP No. 00182C103 13D
       

     

    1.

    Name of Reporting Persons

     

    Meridian Venture Partners II, L.P. (“MVP II”),

     

     
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ¨
         
      (b) x  (1)
         
     
    3.

    SEC Use Only

     

     

     
    4.

    Source of Funds (See Instructions)

     

    OO

     

     
    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
       
     
    6.

    Citizenship or Place of Organization

     

    Delaware

     

     

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

     

    0 Shares

     

     
    8.

    Shared Voting Power

     

    2,019,259 shares of Common Stock

     

     
    9.

    Sole Dispositive Power

     

    0 Shares

     

     
    10.

    Shared Dispositive Power

     

    2,019,259 shares of Common Stock

     

     

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,019,259 shares of Common Stock

     

     
    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
       
     
    13.

    Percent of Class Represented by Amount in Row 11

     

    11.6% (2)

     

     
    14.

    Type of Reporting Person (See Instructions)

     

    PN

     

     

     

     

    (1) This statement on Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2) Percentage is based on 17,453,805 shares of the Company’s Common Stock, par value $0.0001 per share, outstanding as of November 2, 2022, as reported on the Company’s Form 10-Q for the period ended September 30, 2022.

     

     

     

     

    CUSIP No. 00182C103

    13D

       

     

    1.

    Name of Reporting Persons

     

    Meridian Venture Partners II, Co. (“MVP Corp.”)

     

     
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ¨
         
      (b) x (1)
         
     
    3.

    SEC Use Only

     

     

     
    4.

    Source of Funds (See Instructions)

     

    OO

     

     
    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
       
     
    6.

    Citizenship or Place of Organization

     

    Delaware

     

     

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

     

    0 shares

     

     
    8.

    Shared Voting Power

     

    2,019,259 shares of Common Stock

     

     
    9.

    Sole Dispositive Power

     

    0 shares

     

     
    10.

    Shared Dispositive Power

     

    2,019,259 shares of Common Stock

     

     

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,019,259 shares of Common Stock

     

     
    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
       
     
    13.

    Percent of Class Represented by Amount in Row 11

     

    11.6% (2)

     

     
    14.

    Type of Reporting Person (See Instructions)

     

    CO

     

     

     

     

    (1) This statement on Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2) Percentage is based on 17,453,805 shares of the Company’s Common Stock, par value $0.0001 per share, outstanding as of November 2, 2022, as reported on the Company’s Form 10-Q for the period ended September 30, 2022.

     

     

     

     

    CUSIP No. 00182C103 13D
       

     

    1.

    Name of Reporting Persons

     

    Robert E. Brown, Jr.

     

     
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ¨
         
      (b) x  (1)
         
     
    3.

    SEC Use Only

     

     

     
    4.

    Source of Funds (See Instructions)

     

    OO

     

     
    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
       
     
    6.

    Citizenship or Place of Organization

     

    United States of America

     

     

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

     

    49,021 Shares

     

     
    8.

    Shared Voting Power

     

    2,019,259 shares of Common Stock

     

     
    9.

    Sole Dispositive Power

     

    49,021 Shares

     

     
    10.

    Shared Dispositive Power

     

    2,019,259 shares of Common Stock

     

     

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,068,280 shares of Common Stock

     

     
    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
       
     
    13.

    Percent of Class Represented by Amount in Row 11

     

    11.8% (2)

     

     
    14.

    Type of Reporting Person (See Instructions)

     

    IN

     

     

     

     

    (1) This statement on Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2) Percentage is based on 17,453,805 shares of the Company’s Common Stock, par value $0.0001 per share, outstanding as of November 2, 2022, as reported on the Company’s Form 10-Q for the period ended September 30, 2022.

     

     

     

     

    Item 1. Security and Issuer.

     

    This Amendment No. 5 on Schedule 13D (this “Schedule 13D”) relates to ANI Pharmaceuticals, Inc.'s (the “Company”) common stock, $0.0001 par value (the “Common Stock”) and amends and further supplements the Schedule 13D originally filed on July 1, 2013 (as amended from time to time, the “Statement”) by Meridian Venture Partners II GP, L.P., a limited partnership organized under the laws of the State of Delaware (“GP”), Meridian Venture Partners II, L.P., a limited partnership organized under the laws of State of Delaware (“MVP II”), Meridian Venture Partners II, Co., a Delaware corporation (“MVP Corp.”) and Mr. Robert E. Brown, Jr. (collectively with GP, MVP II, and MVP Corp., the “Reporting Persons”). The Reporting Persons are filing this Schedule 13D to report the sale by the Reporting Persons of 200,000 shares of Common Stock on December 1, 2022. Except as expressly set forth herein, there have been no changes to the Statement. The Company’s principal executive offices are located at 210 Main Street West, Baudette, Minnesota 56623.

     

    Item 4. Purpose of Transaction.

     

    The shares of Common Stock owned by the Reporting Persons were acquired solely for investment purposes.

     

    On December 1, 2022, the Reporting Persons sold 200,000 shares of Common Stock for its liquidity purposes, and no additional sales are planned at this time.

     

    Item 5. Interest in Securities of the Issuer.

     

    (a) and (b) Regarding aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person.  Regarding percentage beneficial ownership, see Row 13 of the cover page of each Reporting Person.  Regarding sole power to vote shares, see Row 7 of the cover page of each Reporting Person.  Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person.  Regarding sole power to dispose of shares, see Row 9 of the cover page of each Reporting Person.  Regarding shared power to dispose of shares, see Row 10 of the cover page of each Reporting Person.

     

    (c) During the past sixty days the Reporting Persons sold 200,000 shares of Common Stock at a price per share of $38.50. The Reporting Persons will provide to the Securities Exchange Commission complete information regarding each of these transactions upon request.

     

      (d) Not applicable

     

      (e) Not applicable

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of the undersigned knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    December 12, 2022 Meridian Venture Partners II GP, L.P.
         
      BY: Meridian Venture Partners II, Co.
         
      ITS: GENERAL PARTNER
         
      By: /s/ Robert E. Brown, Jr.
         
        Robert E. Brown, Jr., President

     

    December 12, 2022 Meridian Venture Partners II, L.P.
       
      BY: Meridian Venture Partners II GP, L.P.
         
      ITS: GENERAL PARTNER
         
        BY: Meridian Venture Partners II, Co.
         
        ITS: GENERAL PARTNER
         
      By: /s/ Robert E. Brown, Jr.
         
        Robert E. Brown, Jr., President

     

     

     

     

    December 12, 2022 Meridian Venture Partners II, Co.
         
      By: /s/ Robert E. Brown, Jr.
         
        Robert E. Brown, Jr., President

     

    December 12, 2022 ROBERT E. BROWN, JR.
         
      By: /s/ Robert E. Brown, Jr.
         
        Robert E. Brown, Jr.

     

     

     

    Get the next $ANIP alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ANIP

    DatePrice TargetRatingAnalyst
    7/10/2025$84.00Buy
    H.C. Wainwright
    3/14/2025$80.00Buy
    Jefferies
    3/12/2025$85.00Overweight
    Analyst
    12/11/2024$80.00Outperform
    Leerink Partners
    10/11/2024$68.00Overweight
    Piper Sandler
    3/15/2024$80.00Overweight
    CapitalOne
    8/22/2023$60.00 → $73.00Buy
    H.C. Wainwright
    3/1/2023$55.00Buy
    Guggenheim
    More analyst ratings

    $ANIP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SR. VP, GENERAL COUNSEL & SEC. Cook Meredith covered exercise/tax liability with 2,071 shares, decreasing direct ownership by 3% to 76,874 units (SEC Form 4)

      4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

      7/21/25 4:12:57 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $25,952 worth of shares (400 units at $64.88), decreasing direct ownership by 0.50% to 78,945 units (SEC Form 4)

      4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

      7/14/25 4:11:07 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $24,548 worth of shares (400 units at $61.37), decreasing direct ownership by 0.50% to 79,345 units (SEC Form 4)

      4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

      6/16/25 5:24:45 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on ANI Pharma with a new price target

      H.C. Wainwright initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $84.00

      7/10/25 8:50:19 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on ANI Pharma with a new price target

      Jefferies initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $80.00

      3/14/25 7:26:09 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Analyst initiated coverage on ANI Pharma with a new price target

      Analyst initiated coverage of ANI Pharma with a rating of Overweight and set a new price target of $85.00

      3/12/25 7:20:36 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    Leadership Updates

    Live Leadership Updates

    See more
    • Alcami Announces CEO Transition

      Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries  DURHAM, N.C., Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the resignation of Bill Humphries. Alcami's Board Chair and former Chief Executive Officer Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations and a strong client-centric approach from a proven industry veteran. "On behalf of the Board, I'd like to express gratitude to Bill for his leadership

      1/13/25 11:12:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors

      -- Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience -- Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and specialty and retail pharmacy -- BAUDETTE, Minn., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the addition of Matthew J. Leonard, R.Ph. to its Board of Directors. Mr. Leonard brings more than 35 years of experience as an accomplished leader and innovator within the pharmaceutical industry. This appointment is effective immediately. "We are delighted to add Matthew (Matt) Leonard to our Board of Directors. With his deep leadershi

      8/23/23 6:50:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer

      ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") today announced that Krista L. Davis will join the Company as Chief Human Resources Officer, effective September 12. Ms. Davis brings to the Company over 20 years of executive leadership experience in human resources, talent management, and organizational development. "Ms. Davis is an important addition to our leadership team and will bring strategic and innovative thought leadership to our priority people and organizational issues. Krista has a long track record of driving organizational effectiveness and delivering results across industries and cultures, most recently with Novartis, where she led global human resources for

      9/12/22 6:50:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)

      Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study Enrolled Treatment-Naïve, or Almost Naïve, Patients with DME Results presented by Michael A. Singer, M.D. in a paper-on-demand presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting Conference call scheduled for today at 8:30 am ET PRINCETON, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced results from the NEW DAY clinical trial of ILUVIEN® (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for use in patients with diabetic macula

      7/23/25 6:50:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th

      PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host 1x1 meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on Tuesday, July 8, 2025, in Boston, MA. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company committed to its mission of "Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets n

      7/2/25 6:50:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Announces Presentation of New Preclinical Data

      PRINCETON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced new preclinical data on the use of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) in a mouse model of murine collagen-induced inflammatory arthritis. "In a preclinical model of murine collagen-induced arthritis, repository corticotrophin injection attenuated joint swelling in mice, and decreased inflammatory cytokine response without causing additional bone turnover, as compared to controls," said Mary Pao, MD, PhD, Chief Medical Officer of Rare Disease at ANI. "These data further expand our understanding of Cortrophin Gel's mec

      6/12/25 6:59:59 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for HYDROCODONE BITARTRATE AND IBUPROFEN

      Submission status for ANI PHARMS INC's drug HYDROCODONE BITARTRATE AND IBUPROFEN (SUPPL-6) with active ingredient HYDROCODONE BITARTRATE; IBUPROFEN has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 077454, Application Classification: Labeling

      3/8/21 5:11:24 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OXYCODONE AND ASPIRIN

      Submission status for ANI PHARMS INC's drug OXYCODONE AND ASPIRIN (SUPPL-30) with active ingredient ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 040255, Application Classification: Labeling

      3/8/21 5:11:06 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for EZETIMIBE AND SIMVASTATIN

      Submission status for ANI PHARMS INC's drug EZETIMIBE AND SIMVASTATIN (SUPPL-10) with active ingredient EZETIMIBE; SIMVASTATIN has changed to 'Approval' on 02/23/2021. Application Category: ANDA, Application Number: 201890, Application Classification: Labeling

      2/25/21 5:09:42 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    SEC Filings

    See more
    • ANI Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)

      7/23/25 4:26:37 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)

      7/23/25 6:53:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by ANI Pharmaceuticals Inc.

      S-8 - ANI PHARMACEUTICALS INC (0001023024) (Filer)

      7/11/25 4:19:26 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    Financials

    Live finance-specific insights

    See more
    • ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)

      Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study Enrolled Treatment-Naïve, or Almost Naïve, Patients with DME Results presented by Michael A. Singer, M.D. in a paper-on-demand presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting Conference call scheduled for today at 8:30 am ET PRINCETON, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced results from the NEW DAY clinical trial of ILUVIEN® (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for use in patients with diabetic macula

      7/23/25 6:50:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

      Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4%Total Rare Disease quarterly net revenues of $69.0 million, which includes: Purified Cortrophin® Gel net revenues of $52.9 million, an increase of 43.1% year-over-year, andILUVIEN® and YUTIQ® net revenues of $16.1 million Record Generics net revenues of $98.7 million, an increase of 40.5% year-over-yearDelivered record quarterly adjusted non-GAAP EBITDA of $50.7 million, an increase of 34.9% year-over-yearDiluted GAAP income per share of $0.69 and record adjusted non-GAAP diluted earnings per share of $1.70Increased 2025 guidance with expected net revenues of $768.0 million to $793.0 million

      5/9/25 6:50:08 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET

      PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: DateFriday, May 9, 2025 Time8:00 a.m. ET Toll free (U.S.)800-225-9448 Conference ID4921902 Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section           A re

      4/9/25 6:50:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ANI Pharmaceuticals Inc.

      SC 13G/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)

      11/13/24 4:30:24 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ANI Pharmaceuticals Inc. (Amendment)

      SC 13D/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)

      3/14/24 7:30:38 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ANI Pharmaceuticals Inc.

      SC 13G - ANI PHARMACEUTICALS INC (0001023024) (Subject)

      2/13/24 4:58:56 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care